TrakCel, a software developer for cell and gene therapy supply chain tracking systems, and WuXi AppTec Advanced Therapies, a CDMO, have entered a collaborative agreement that aims to accelerate the seamless delivery of advanced therapy treatments to bring an end-to-end solution to mutual customers.
 
To provide full visibility and control of their collection-to-administration supply chain, cell therapy companies need to ensure consistent product handling and data capture across all supply chain partners. This is increasingly being achieved through the deployment of supply chain management software, such as TrakCel’s platform. Challenges can arise if software-driven workflows do not account for established processes in place at each supply chain partner. For example, if a contract manufacturer needs to change their processes to fit in with those designed into supply chain management software, this can increase costs and timelines for software adoption. Conversely, rewriting software after it becomes apparent that it will not work for a contract manufacturer also incurs additional expense and can delay software deployment. 
 
WuXi AppTec Advanced Therapies will leverage configured manufacturing module in TrakCel’s software, based around WuXi’s current standard operating procedures and preferred workflows. WuXi AppTec Advanced Therapies was the first CDMO to use TrakCel’s software and its Philadelphia, PA site currently has a greater number of users than any other facility in the supply chain. The resultant pre-built manufacturing module in the TrakCel platform aims to shorten the time and costs associated with deploying an end-to-end solution to TrakCel and WuXi’s mutual clients.
 
Both companies will continue to build on their partnership by exploring opportunities to further enhance their combined service to their mutual customers.
 
“As one of the first CDMOs to use TrakCel’s software and the supply chain partner with more users than any other facility, WuXi AppTec Advanced Therapies is well placed to collaborate with TrakCel to identify a more efficient way of working together. It is the latest development in TrakCel’s formation of an international partner ecosystem of connected and complementary cell and gene therapy service providers. This partner ecosystem as a result now includes a commercial scale, third party manufacturing company,” said Ravi Nalliah, CEO, TrakCel. “The TrakCel partnership with WuXi AppTec Advanced Therapies will enable both companies to move towards increased standardization and improved delivery of these innovative treatments to patients around the world.”  
 
“We are pleased to establish a collaborative agreement with TrakCel to support customers that seek to promote streamlining personalized therapies from specimen connections to manufacturing,” said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies. “With our leading integrated manufacturing and testing services, we believe we can bring even more speed, reliability and security to an already complex manufacturing and supply chain. We are committed to helping our partners deliver more innovative therapies to patients and the market sooner.”